{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Propofol's Immunomodulatory Effects in Sepsis"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was computer-generated"
      },
      "Participants": {
        "score": 2,
        "evidence": "Peripheral blood monocytes from septic patients and healthy volunteers were also studied"
      },
      "Intervention": {
        "score": 2,
        "evidence": "macrophages from Rab5a\u2212/\u2212 and WT mice treated with lipopolysaccharide (LPS) or cecal ligation and puncture (CLP)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the mechanisms underlying propofol's immunomodulatory activity"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in membrane TLR4 expression, measured over 24 hours"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Propofol significantly reduced membrane TLR4 expression on macrophages in vitro and in vivo"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not specified"
      }
    },
    "total_score": 15,
    "max_score": 25
  },
  "model": "gpt-4o"
}